Recro Pharma – $15 Million Follow-On

New York – August 30, 2016 – Cooley advised the underwriters on Recro Pharma's $14.9 million follow-on offering of 1,986,666 shares of common stock.

Recro Pharma, which trades on The NASDAQ Capital Market as "REPH," is a specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain.

Piper Jaffray & Co. acted as sole book-running manager for the offering and Janney Montgomery Scott acted as co-manager.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

 

Related Contacts
Div Gupta Partner, New York
Brian Leaf Partner, Reston
Brent Siler Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Ivor Elrifi Partner, New York
Heidi A. Erlacher Partner in Charge - Boston
Francis Wheeler Partner, Colorado
Phil Mitchell Partner, New York
Madison Jones Associate, Washington, DC
Pia Kaur Associate, New York